NRS
BMY.RT

Neville Rodie & Shaw’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Neville Rodie & Shaw’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-82,984
Closed -$57K – 261
2020
Q4 		$57K Sell
82,984
-5,525
-6% -$11.8K ﹤0.01% 252
2020
Q3 		$199K Hold
88,509
– – 0.02% 232
2020
Q2 		$317K Sell
88,509
-3,900
-4% -$14.1K 0.03% 187
2020
Q1 		$351K Hold
92,409
– – 0.04% 171
2019
Q4 		$278K Buy
+92,409
New +$240K 0.03% 215

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Neville Rodie & Shaw's BMY.RT Position: Q1 2021 in Review

Neville Rodie & Shaw sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 82,984 shares — an estimated $57K sold.

Neville Rodie & Shaw first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $351K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Neville Rodie & Shaw reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Neville Rodie & Shaw sold 82,984 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $57K.
  • Neville Rodie & Shaw first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Neville Rodie & Shaw's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $351K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Neville Rodie & Shaw's 13F filing for Q1 2021, filed 8 Apr 2021.